538 results on '"Ozelo, Margareth"'
Search Results
2. Cost of hemophilia A in Brazil: a microcosting study
3. Comparative transcriptomic analysis of circulating endothelial cells in sickle cell stroke
4. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A
5. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A
6. Utilizing artificial intelligence for the detection of hemarthrosis in hemophilia using point-of-care ultrasonography
7. Extended half-life recombinant factor VIII treatment of hemophilia A in Brazil: an expert consensus statement
8. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1
9. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?
10. Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
11. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
12. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
13. Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature
14. The translational gap for gene therapies in low- and middle-income countries
15. Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond
16. Current and emerging Gene Therapies for Haemophilia A and B
17. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
18. The molecular mechanism responsible for HbSC retinopathy may depend on the action of the angiogenesis-related genes ROBO1 and SLC38A5.
19. The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study
20. Knee radiosynovectomy with 153Sm-hydroxyapatite compared to 90Y-hydroxyapatite: initial results of a prospective trial
21. Prolonged APTT of unknown etiology: A systematic evaluation of causes and laboratory resource use in an outpatient hemostasis academic unit
22. Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries
23. Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B
24. Promoting pain coping skills in haemophilia: A remote intervention integrating exercise and pain education.
25. Guideline on immune thrombocytopenia in adults: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Project guidelines: Associação Médica Brasileira – 2018
26. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
27. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A
28. Hypercoagulability and Sickle Cell Disease
29. Comparative transcriptome analysis of endothelial progenitor cells of HbSS patients with and without proliferative retinopathy
30. Post hoc longitudinal assessment of efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
31. First hemophilia B gene therapy approved: More than two decades in the making
32. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors
33. Radiosynovectomy of the ankle in hemophilic arthropathy: effectiveness of samarium-153 and yttrium-90
34. Gene therapy for hemophilia: looking beyond factor expression
35. Extended half-life recombinant factor VIII treatment of hemophilia A in Brazil: an expert consensus statement
36. Chronic pain in patients with hemophilia: Influence of kinesiophobia and catastrophizing thoughts
37. Incidence of Inhibitors in Previously Untreated Patients with Severe Hemophilia a Treated with Plasma-Derived Vs. Recombinant Factor VIII Concentrates: A Systematic Review and Meta-Analyses
38. Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
39. Impaired repair properties of endothelial colony‐forming cells in patients with granulomatosis with polyangiitis
40. Immunogenicity of Current and New Therapies for Hemophilia A
41. International consensus recommendations on the management of people with haemophilia B.
42. Surgery in patients with hemophilia: Is thromboprophylaxis mandatory?
43. Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
44. Recent advances in therapeutic options for rare hemostatic disorders: selected poster extracts of recent research in hemophilia A, congenital hemophilia with inhibitors, von Willebrand disease, and thrombotic thrombocytopenic purpura presented at the 29th congress of the International Society on Thrombosis and Haemostasis (ISTH 2021, Jul 17–21; virtual congress)
45. Haemophilia gene therapy—Update on new country initiatives
46. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
47. Impact of novel hemophilia therapies around the world
48. sj-docx-1-tah-10.1177_20406207221085202 – Supplemental material for International consensus recommendations on the management of people with haemophilia B
49. International consensus recommendations on the management of people with haemophilia B
50. Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.